KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Other Working Capital Changes (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Other Working Capital Changes for 8 consecutive years, with -$209000.0 as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes rose 61.08% to -$209000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.3 million through Dec 2025, down 211.65% year-over-year, with the annual reading at -$1.3 million for FY2025, 211.65% down from the prior year.
  • Other Working Capital Changes hit -$209000.0 in Q4 2025 for Castle Biosciences, up from -$5.8 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $3.4 million in Q1 2025 to a low of -$5.8 million in Q3 2025.
  • Historically, Other Working Capital Changes has averaged -$37050.0 across 5 years, with a median of -$148500.0 in 2022.
  • Biggest five-year swings in Other Working Capital Changes: plummeted 1401.55% in 2021 and later surged 1362.61% in 2025.
  • Year by year, Other Working Capital Changes stood at -$1.6 million in 2021, then skyrocketed by 95.27% to -$75000.0 in 2022, then crashed by 221.33% to -$241000.0 in 2023, then crashed by 122.82% to -$537000.0 in 2024, then surged by 61.08% to -$209000.0 in 2025.
  • Business Quant data shows Other Working Capital Changes for CSTL at -$209000.0 in Q4 2025, -$5.8 million in Q3 2025, and $1.3 million in Q2 2025.